Litigation Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)

« Back to Dashboard

Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)

Docket	1:20-cv-00133	Date Filed	2020-01-28
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	Defendant	Referred To
Parties	GLENMARK PHARMACEUTICALS LIMITED
Patents	10,543,179; 9,187,405
Attorneys	Sarah E. Spires
Firms	Stamoulis & Weinblatt LLC
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-01-28				External link to document
2020-01-28	1	Complaint	mg, prior to expiration of U.S. Patent No. 10,543,179 (“the ’179 patent”). ME1 32500579v.1 Case 1…. This is an action for patent infringement arising under the patent laws of the United States, …prior to the expiration of U.S. Patent No. 9,187,405 (“the ’405 patent”). 9. In …)(IV), with respect to the ’405 patent asserting that the ’405 patent is invalid, unenforceable, and/…20 Page 7 of 40 PageID #: 7 patent asserting that the ’405 patent is invalid, unenforceable, and/or	External link to document
2020-01-28	125	Notice of Service	' Invalidity Contentions Regarding U.S. Patent No. 10,543,179 filed by Novartis Pharmaceuticals Corporation… 28 January 2020 1:20-cv-00133 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2020-01-28	132	Notice of Service	HECs Invalidity Contentions Regarding U.S. Patent No. 10,543,179 filed by HEC Pharm Co., Ltd., HEC Pharm … 28 January 2020 1:20-cv-00133 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document
2020-01-28	149	Notice of Service	Final Invalidity Contentions Regarding U.S. Patent No. 10,543,179 filed by Novartis Pharmaceuticals Corporation… 28 January 2020 1:20-cv-00133 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd. Litigation Summary and Patent Analysis, 1:20-cv-00133

Last updated: October 9, 2026

Novartis Pharmaceuticals Corporation sued HEC Pharm Co., Ltd. in the District of Delaware after HEC filed an abbreviated new drug application seeking approval for generic sacubitril/valsartan, the active pharmaceutical combination in Entresto. The dispute centered on U.S. Patent No. 8,101,659, which covers pharmaceutical compositions and therapeutic use of sacubitril with valsartan.

The case ended with the asserted Entresto patent claims being held invalid as obvious. The Federal Circuit later affirmed the district court’s judgment. The decision materially reduced Novartis’s ability to use the ’659 patent to delay HEC’s generic entry, although separate Orange Book patents, regulatory exclusivity, settlement terms, and commercial launch restrictions could still affect the timing of market entry.

What was the Novartis v. HEC Pharm case about?

Novartis filed the action under the Hatch-Waxman Act after HEC submitted an ANDA for generic sacubitril/valsartan tablets. HEC’s ANDA included a Paragraph IV certification asserting that the relevant Novartis patent was invalid, unenforceable, or would not be infringed by HEC’s proposed product.

The case was filed in the U.S. District Court for the District of Delaware under case number 1:20-cv-00133. Novartis alleged infringement under 35 U.S.C. § 271(e)(2), which treats the filing of an ANDA with a Paragraph IV certification as an artificial act of patent infringement.

Case element	Detail
Plaintiff	Novartis Pharmaceuticals Corporation
Defendant	HEC Pharm Co., Ltd.
Court	U.S. District Court for the District of Delaware
Case number	1:20-cv-00133
Product	Generic sacubitril/valsartan tablets
Reference product	Entresto
FDA pathway	ANDA under the Hatch-Waxman Act
Principal patent	U.S. Patent No. 8,101,659
Central defense	Invalidity, including obviousness
Result	Asserted claims held invalid; judgment affirmed on appeal

The dispute was commercially significant because Entresto is one of Novartis’s largest products and because sacubitril/valsartan has no biologic component. Biosimilar approval standards therefore do not apply. The relevant competitive threat is abbreviated generic entry.

What patents protect Entresto and sacubitril/valsartan?

The principal patent litigated against HEC was U.S. Patent No. 8,101,659, commonly referred to as the ’659 patent. The patent covers pharmaceutical compositions containing sacubitril and valsartan and methods involving the combination.

The patent’s commercial significance came from the combination of two pharmacologically active components:

• Sacubitril, a neprilysin inhibitor.
• Valsartan, an angiotensin II receptor blocker.

The marketed product uses a fixed-combination form of the two agents. The case required the court to assess whether a skilled person would have been motivated to combine the known neprilysin-inhibition and angiotensin-receptor-blockade approaches, and whether the claimed combination had a sufficient expectation of success.

The patent estate around Entresto has included composition, formulation, method-of-use, and later-filed patents. Not every Orange Book-listed patent was necessarily adjudicated in the HEC case. The ’659 patent was the central patent in the reported judgment.

Patent timeline

Event	Date or period
’659 patent issued	2012
Novartis sued HEC	2020
District court invalidity judgment	2022
Federal Circuit appeal	2023-2024
Federal Circuit disposition	Judgment affirmed
Original ’659 patent term	Generally extending into 2026, subject to patent-term adjustments or extensions

The exact commercial effect of the expiration date depends on the patent claims remaining enforceable, any pediatric extension, other listed patents, and any settlement or launch license applicable to a specific ANDA applicant.

Why did the court hold the Entresto patent claims obvious?

The district court focused on the obviousness framework under 35 U.S.C. § 103. The analysis considered the scope and content of the prior art, the differences between the prior art and the asserted claims, the level of ordinary skill, and objective indicia of nonobviousness.

The court concluded that the asserted claims were obvious. The decision treated the prior art as providing a motivation to combine neprilysin inhibition with angiotensin receptor blockade in the treatment of cardiovascular disease. The court also found that the skilled artisan would have had a reasonable expectation of success.

The core legal issue was not whether Entresto had commercial value. It was whether the claimed combination was an inventive advance over the prior art at the relevant filing date.

Key obviousness issues

Motivation to combine

Novartis argued that the prior art did not provide a sufficient reason to select the claimed combination and dosage relationship. HEC argued that the prior art identified the therapeutic rationale for combining neprilysin inhibition and angiotensin receptor blockade.

The court accepted HEC’s position that the prior art supplied an adequate reason to pursue the combination.

Reasonable expectation of success

The court also rejected the argument that uncertainty in clinical development prevented a finding of obviousness. A reasonable expectation of success does not require certainty or a guaranteed clinical outcome. The relevant question is whether the skilled artisan would have reasonably expected the claimed approach to work based on the available evidence.

Objective indicia

Novartis relied on commercial success, industry recognition, licensing history, and clinical results as secondary considerations. The court did not find those factors sufficient to overcome the prior-art showing. Objective evidence must have a nexus to the claimed invention, and commercial success alone does not establish nonobviousness.

What did the Federal Circuit decide?

The Federal Circuit affirmed the district court’s judgment that the asserted claims were invalid as obvious. The appellate decision left the central holding intact: the ’659 patent could not be enforced to block HEC’s ANDA product on the basis of the claims adjudicated in the case.

The appellate outcome had three practical consequences:

1. Novartis could not rely on the invalidated ’659 claims to obtain an injunction against HEC’s ANDA product.
2. HEC’s Paragraph IV invalidity position was ultimately successful as to those claims.
3. Any remaining entry barrier had to come from another enforceable patent, regulatory exclusivity, a settlement, or commercial launch restrictions.

The appellate decision did not convert HEC’s ANDA into immediate FDA approval. Patent invalidity and FDA approval are separate questions. HEC still needed to satisfy FDA requirements applicable to its ANDA, including chemistry, manufacturing, controls, labeling, bioequivalence, and inspection requirements.

What was the Paragraph IV challenge and 30-month stay?

HEC’s Paragraph IV certification triggered Novartis’s statutory right to sue. Because Novartis filed suit within the applicable 45-day period, the FDA’s approval of HEC’s ANDA was subject to the Hatch-Waxman 30-month stay, unless the stay was shortened, terminated, or otherwise affected by subsequent court action.

The Paragraph IV process created the following sequence:

Step	Legal effect
HEC submitted ANDA	Sought approval of generic sacubitril/valsartan
HEC filed Paragraph IV certification	Alleged patent invalidity, unenforceability, or noninfringement
Novartis filed infringement action	Created statutory patent litigation
30-month stay began	Temporarily restricted FDA approval
Court held patent claims invalid	Removed the principal patent-based barrier tied to those claims
Appeal affirmed	Confirmed the invalidity judgment

A successful Paragraph IV certification does not itself guarantee immediate launch. The applicant must also account for FDA approval status, other patents, exclusivity periods, litigation involving other applicants, and any contractual restrictions.

What was the litigation status and procedural outcome?

The litigation progressed through district court proceedings addressing claim validity and then appellate review. The decisive issue was patent validity rather than a permanent injunction based on infringement.

Procedural timeline

Date	Event
2020	Novartis filed the Hatch-Waxman action against HEC in Delaware
2020-2022	Parties litigated infringement, validity, claim construction, expert testimony, and prior art
2022	District court entered judgment holding the asserted ’659 claims invalid as obvious
2023-2024	Federal Circuit reviewed the judgment
2024	Federal Circuit affirmed the district court’s result

The case illustrates the risk of relying on a single primary composition patent when the asserted claims cover a combination that can be reconstructed from multiple prior-art references. A successful invalidity challenge can eliminate the principal litigation-based launch barrier even before the patent’s nominal expiration date.

Were there settlement agreements affecting HEC?

The reported judgment reflects adjudication of the dispute rather than a publicly identified settlement disposition between Novartis and HEC. A settlement may still affect the commercial timing of a particular ANDA applicant if the parties entered into confidential or later-publicized arrangements, but the court’s invalidity judgment is the controlling reported outcome for the litigated patent claims.

Settlement agreements in pharmaceutical patent cases commonly address:

• Authorized or licensed generic launch dates.
• Restrictions on launch before a specified patent date.
• Allocation of first-filer or exclusivity rights.
• Covenants not to sue.
• Supply or licensing arrangements.
• Treatment of later-issued formulation or method-of-use patents.

The invalidity judgment reduced Novartis’s leverage in negotiating restrictions tied solely to the ’659 patent.

What is the FDA and Orange Book status of Entresto?

Entresto is an FDA-approved fixed-dose combination of sacubitril and valsartan. It is approved for cardiovascular indications, including heart failure with reduced ejection fraction and other labeled heart-failure populations.

The Orange Book identifies patents and regulatory exclusivities associated with approved drug products. An Orange Book listing does not establish patent validity. It gives an ANDA applicant a mechanism to address the listed patent through Paragraph I, II, III, or IV certification.

For Entresto, the commercial analysis must separate:

Issue	Effect
FDA approval	Determines whether the generic can be approved
Orange Book listing	Identifies patents requiring certification
Paragraph IV certification	Creates potential patent litigation
Patent invalidity	Removes enforceability of adjudicated claims
Patent expiration	Ends enforceable patent rights for expired claims
Regulatory exclusivity	Can independently delay approval
Manufacturing approval	Determines whether the applicant can commercially supply product

The ’659 patent ruling did not invalidate every possible patent relevant to Entresto. Later-issued formulation or method-of-use patents may raise separate questions, especially if an ANDA applicant seeks approval for uses covered by those patents or if the applicant uses a carve-out label.

How strong is the Novartis Entresto patent estate after the HEC decision?

The estate is weaker than before the HEC judgment because the principal patent used in the case was held invalid. The decision also creates persuasive risk for related patents that rely on similar prior-art combinations or overlapping obviousness theories.

The estate may still retain value through:

• Later-issued formulation patents.
• Patents directed to particular dosage forms or release characteristics.
• Method-of-use patents covering narrower patient populations.
• Manufacturing and solid-state patents.
• Patents with claims not adjudicated in the HEC action.
• Regulatory exclusivity or approved-label protections.

The strength of those rights depends on claim scope, written-description support, prosecution history, prior-art differences, and whether a generic applicant can omit the protected indication from its labeling.

Patent-strength assessment

Factor	Assessment
Primary composition patent	Significantly weakened by invalidity judgment
Obviousness vulnerability	High for broad combination claims
Formulation patents	Potentially stronger if technically narrow and supported by unexpected results
Method-of-use patents	Dependent on label scope and carve-out feasibility
Manufacturing patents	Potential barrier if the generic process necessarily practices the claims
Litigation leverage	Reduced after Federal Circuit affirmance
Generic entry risk	High once FDA and remaining-patent conditions are satisfied

What generic launch risks exist for sacubitril/valsartan?

The most likely generic-entry pathway is staged rather than immediate. The principal patent judgment favors generic competition, but the commercial launch date can still be affected by FDA review, other patents, ANDA-specific litigation, and market strategy.

Generic launch scenarios

Scenario 1: FDA approval after patent resolution

If HEC receives final ANDA approval and no enforceable patent or exclusivity block remains, HEC could launch subject to ordinary pharmaceutical supply and commercialization requirements.

Scenario 2: Approval with a label carve-out

If a remaining method-of-use patent covers only a specific indication, HEC may seek approval with a section viii statement removing that use from its label. Novartis could still challenge whether the proposed label induces infringement.

Scenario 3: Launch after negotiated license date

HEC could launch under a settlement or license that permits entry before or after nominal patent expiration. The public court judgment does not by itself disclose all commercial terms of a private agreement.

Scenario 4: Delayed launch despite invalidity

FDA deficiencies, manufacturing readiness, inspection delays, or unresolved patents can delay commercial entry even after the primary patent is invalidated.

How does HEC compare with other generic challengers?

HEC’s case is important because it produced a litigated invalidity judgment rather than leaving the ’659 patent’s enforceability unresolved through a settlement. Other ANDA applicants may benefit from the judgment through collateral litigation strategy, although the legal effect depends on party identity, claim overlap, and estoppel rules.

The competitive field for sacubitril/valsartan includes large generic manufacturers and regional suppliers that may have filed their own ANDAs or entered settlements with Novartis. Each applicant’s risk profile depends on:

• The timing of its ANDA filing.
• Whether it is a first filer.
• The patents certified under Paragraph IV.
• The claims remaining in force.
• The proposed label.
• Manufacturing and supply capability.
• Any launch agreement with Novartis.

A ruling against the primary patent generally lowers entry barriers for the entire generic class, but it does not automatically resolve every applicant’s litigation.

What revenue exposure does the HEC decision create for Novartis?

Entresto has been a major Novartis growth product, with annual sales reaching several billion dollars globally. U.S. generic entry could reduce net sales through price erosion, payer substitution, formulary pressure, and loss of market share.

The revenue impact depends on:

• Number of approved generic competitors.
• Timing of the first commercial launch.
• Whether HEC receives 180-day exclusivity.
• Generic discount levels.
• Prescriber and payer switching.
• Persistence of brand loyalty.
• International patent and regulatory timelines.
• Novartis contracting and authorized-generic strategy.

The first generic entrant may achieve materially higher margins than later entrants. Once multiple suppliers enter, prices typically decline more rapidly and branded market share becomes harder to defend.

Key Takeaways

• Novartis sued HEC after a Paragraph IV challenge to Entresto-related patent rights.
• The central patent was U.S. Patent No. 8,101,659.
• The District of Delaware held the asserted claims invalid as obvious.
• The Federal Circuit affirmed the invalidity result.
• The ruling removed the principal patent-based barrier associated with the HEC litigation.
• FDA approval, remaining Orange Book patents, regulatory exclusivity, and manufacturing readiness remain separate launch conditions.
• The decision increases generic-entry risk for sacubitril/valsartan and reduces Novartis’s leverage over ANDA applicants relying on the same invalidated patent.
• Later formulation, method-of-use, solid-state, or manufacturing patents must be analyzed separately.
• The commercial effect is potentially substantial because Entresto is a multibillion-dollar Novartis product.

FAQs About Novartis v. HEC Pharm

What drug was at issue in Novartis v. HEC Pharm?

The case involved HEC’s proposed generic version of sacubitril/valsartan, the active combination in Novartis’s Entresto product.

Did HEC win the Entresto patent case?

HEC prevailed on the central validity issue. The asserted claims of the ’659 patent were held invalid as obvious, and the Federal Circuit affirmed the result.

Does the ruling mean generic Entresto launched immediately?

No. Patent invalidity does not substitute for FDA approval, manufacturing readiness, or resolution of other patents and regulatory exclusivities.

What was the most important patent in the case?

U.S. Patent No. 8,101,659 was the principal patent litigated in the reported action. Its invalidity materially weakened Novartis’s patent position for the claimed sacubitril/valsartan combination.

Are Entresto formulation patents still relevant after the HEC decision?

Yes. The HEC judgment does not automatically invalidate every patent covering Entresto, including later-issued formulation, method-of-use, solid-state, or manufacturing patents.

References

1. U.S. District Court for the District of Delaware. (2020-2022). Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., No. 1:20-cv-00133.

2. U.S. Court of Appeals for the Federal Circuit. (2024). Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., appeal from the U.S. District Court for the District of Delaware.

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,101,659.

5. Novartis Pharmaceuticals Corporation. (n.d.). Entresto prescribing information. U.S. Food and Drug Administration.